Geode Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-185,982
Closed -$1.18M 4879
2022
Q4
$1.18M Hold
185,982
﹤0.01% 3278
2022
Q3
$952K Buy
185,982
+7,043
+4% +$44.2K ﹤0.01% 3416
2022
Q2
$1.12M Buy
178,939
+33,508
+23% +$113K ﹤0.01% 3375
2022
Q1
$516K Hold
145,431
﹤0.01% 3919
2021
Q4
$730K Hold
145,431
﹤0.01% 3859
2021
Q3
$1.06M Buy
145,431
+15,152
+12% +$104K ﹤0.01% 3641
2021
Q2
$1.12M Buy
130,279
+75,279
+137% +$642K ﹤0.01% 3533
2021
Q1
$595K Buy
55,000
+35,668
+185% +$346K ﹤0.01% 3747
2020
Q4
$190K Sell
19,332
-2
-0% -$13 ﹤0.01% 3904
2020
Q3
$103K Hold
19,334
﹤0.01% 3901
2020
Q2
$113K Hold
19,334
﹤0.01% 3816
2020
Q1
$71K Hold
19,334
﹤0.01% 3854
2019
Q4
$122K Hold
19,334
﹤0.01% 3936
2019
Q3
$270K Sell
19,334
-87
-0.4% -$1.43K ﹤0.01% 3680
2019
Q2
$286K Sell
19,421
-11,277
-37% -$302K ﹤0.01% 3672
2019
Q1
$1.29M Buy
30,698
+1,483
+5% +$62.5K ﹤0.01% 3058
2018
Q4
$1.21M Buy
29,215
+2,349
+9% +$106K ﹤0.01% 3026
2018
Q3
$1.29M Buy
26,866
+7,186
+37% +$360K ﹤0.01% 3105
2018
Q2
$932K Buy
19,680
+7,164
+57% +$398K ﹤0.01% 3213
2018
Q1
$769K Hold
12,516
﹤0.01% 3239
2017
Q4
$673K Hold
12,516
﹤0.01% 3247
2017
Q3
$843K Buy
12,516
+7,472
+148% +$428K ﹤0.01% 3186
2017
Q2
$273K Buy
+5,044
New +$234K ﹤0.01% 3573

Geode Capital Management's FSTX Position: Q1 2023 in Review

Geode Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 185,982 shares — an estimated $1.18M sold.

Geode Capital Management first reported a position in FSTX in Q2 2017 and held it in 23 quarters. The position peaked at $1.29M in Q3 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Geode Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Geode Capital Management sold 185,982 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.18M.
  • Geode Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 23 quarters.
  • Geode Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $1.29M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.